BTAI - BioXcel Therapeutics, Inc.

1.48
-0.130   -8.784%

Share volume: 2,900,127
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.61
-0.13
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.50%
1 Month
-5.73%
3 Months
-32.73%
6 Months
-65.01%
1 Year
-50.17%
2 Year
-52.56%
Key data
Stock price
$1.48
P/E Ratio 
0.00
DAY RANGE
$1.47 - $1.60
EPS 
-$10.41
52 WEEK RANGE
$1.17 - $8.08
52 WEEK CHANGE
-$50.17
MARKET CAP 
37.265 M
YIELD 
N/A
SHARES OUTSTANDING 
21.869 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-10-2025
NEXT EARNINGS DATE
05-08-2025
BETA 
1.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,371,704
AVERAGE 30 VOLUME 
$2,758,589
Company detail
CEO: Vimal D. Mehta
Region: US
Website: bioxceltherapeutics.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioXcel Therapeutics, Inc. uses artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Recent news